Article
Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer.
Lung cancer (Amsterdam, Netherlands) - 1 Jan 2014
Yamaguchi Norihiro, Lucena-Araujo Antonio R, Nakayama Sohei, de Figueiredo-Pontes Lorena L, Gonzalez David A, Yasuda Hiroyuki, Kobayashi Susumu, Costa Daniel B
Abstract excerpt
INTRODUCTION: The multitargeted tyrosine kinase inhibitor (TKI) crizotinib is active against ALK translocated non-small-cell lung cancer (NSCLC); however acquired resistance invariably develops over time. ALK mutations have previously been implicated in only a third of resistant tumors. We sought to evaluate alternative mechanisms of resistance and preclinical strategies to overcome these in a cell line driven by...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.